期刊文献+

The Role of Macrophage-Derived Exosomes in Liver Diseases

原文传递
导出
摘要 Exosomes(exos)widely distributed in a variety of biological fluids,including blood,urine,saliva,sputum,breast milk,cerebrospinal fluid,and ascites,contain specific bioactive contents which are involved in physiological and pathological processes,such as signal molecular transfer,substance metabolism,gene regulation,and immune regulation.Macrophages are important innate immune cells which usually act as the first line of defense against infection,and can switch between different functional phenotypes in response to the changes around the microenvironment.Evidence suggests that macrophage-derived exos exert a crucial effect on infection,inflammation,regeneration,tumors,fibrosis,and other lesions in multiple human diseases.However,the role and mechanism of macrophage-derived exos in liver diseases remain to be explored.This review summarizes the current researches on the role and possible mechanism of macrophage-derived exos in liver diseases,with the purpose of providing new potential targets and directions for diagnostic biomarker and clinical treatment of liver diseases.
出处 《Infectious Diseases & Immunity》 2022年第1期34-41,共8页 感染性疾病与免疫(英文)
基金 This study was supported by National Science and Technology Key Project on“Major Infectious Diseases such as HIV/AIDS,Viral Hepatitis Prevention and Treatment”(No.2017ZX10203201-005) National Key R&D Program of China(No.2017YFA0103000) Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support(No.ZYLX201806) Beijing Advanced Innovation Center for Big Data-Based Precision Medicine(No.1212040205) Beijing Municipal Natural Science Foundation(No.7202068) the YouAn fund for liver diseases and AIDS(YNKTTS201801189).
  • 相关文献

参考文献3

二级参考文献43

  • 1Nobili V, Alkhouri N, Alisi A, Della Corte C, Fitzpatrick E, RaponiM, Dhawan A. Nonalcoholic fatty liver disease: a challenge for pediatricians. JAMA Pediatr 2015; 169: 170-176 [PMID: 25506780DOI: 10.1001/jamapediatrics.2014.2702].
  • 2Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, ContrerasM, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liverdisease and nonalcoholic steatohepatitis among a largely middleagedpopulation utilizing ultrasound and liver biopsy: a prospectivestudy. Gastroenterology 2011; 140: 124-131 [PMID: 20858492DOI: 10.1053/j.gastro.2010.09.038].
  • 3Anstee QM, Targher G, Day CP. Progression of NAFLD todiabetes mellitus, cardiovascular disease or cirrhosis. Nat RevGastroenterol Hepatol 2013; 10: 330-344 [PMID: 23507799 DOI:10.1038/nrgastro.2013.41].
  • 4Vernon G, Baranova A, Younossi ZM. Systematic review: theepidemiology and natural history of non-alcoholic fatty liver diseaseand non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther2011; 34: 274-285 [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x].
  • 5Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histologyin obese patients undergoing bariatric surgery. J Hepatol 2006; 45:600-606 [PMID: 16899321].
  • 6Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E,Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and itsconnection with insulin resistance, dyslipidemia, atherosclerosisand coronary heart disease. Nutrients 2013; 5: 1544-1560 [PMID:23666091 DOI: 10.3390/nu5051544].
  • 7Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA,Younossi ZM, Ahmed A. Nonalcoholic steatohepatitis is the secondleading etiology of liver disease among adults awaiting livertransplantation in the United States. Gastroenterology 2015; 148:547-555 [PMID: 25461851 DOI: 10.1053/j.gastro.2014.11.039].
  • 8Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, HuiJM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, WeltmanM, George J. NASH and insulin resistance: Insulin hypersecretionand specific association with the insulin resistance syndrome.Hepatology 2002; 35: 373-379 [PMID: 11826411].
  • 9Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A,Erbel R, Blankstein R, Feldman T, Al-Mallah MH, Santos RD,Budoff MJ, Nasir K. A systematic review: burden and severity ofsubclinical cardiovascular disease among those with nonalcoholicfatty liver; should we care- Atherosclerosis 2013; 230: 258-267[PMID: 24075754 DOI: 10.1016/j.atherosclerosis.2013.07.052].
  • 10Than NN, Newsome PN. A concise review of non-alcoholicfatty liver disease. Atherosclerosis 2015; 239: 192-202 [PMID:25617860 DOI: 10.1016/j.atherosclerosis.2015.01.001].

共引文献419

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部